Metagenomi Therapeutics, Inc. (MGX)

Metagenomi Therapeutics' stock has experienced significant volatility and a notable decline over the past six months. Key events impacting the stock price include Q2 2025 financial results with a substantial net loss, Q3 2025 financial results with a strategic pipeline prioritization and leadership updates, preclinical data presentations, a corporate name change, and regulatory milestones.

Demand for Metagenomi Therapeutics' products and services is not typically subject to seasonal fluctuations. The demand for such specialized medical treatments is driven by disease prevalence, clinical trial outcomes, regulatory approvals, and medical need, rather than seasonal patterns.

Metagenomi Therapeutics, Inc. is a genetic medicines company focused on developing curative therapeutics through its metagenomics-derived genome editing toolbox. The company operates in the healthcare sector, specifically in the biotechnology and biological products industry. Metagenomi's platform is designed to correct genetic mutations and includes technologies like programmable nucleases and CRISPR-associated transposases. The company focuses on in vivo gene editing for its pipeline, while also pursuing technology out-licensing for ex vivo cell therapy, and leverages AI and machine learning in its discovery platform.

Metagenomi Therapeutics, Inc. is headquartered in Emeryville, California, United States. The company develops therapeutics in the United States, with its primary operational and developmental footprint concentrated in the U.S.

Metagenomi Therapeutics' brand reputation has been influenced by scientific progress and financial challenges. Positive impacts include positive preclinical data for its lead hemophilia A program, advancements in its gene editing platform, and collaborations with companies like Ionis Pharmaceuticals. Negative impacts include the decline in stock price, substantial net losses, workforce reduction, and the termination of a partnership with Moderna.

Metagenomi Therapeutics, Inc. has 93 institutional owners and shareholders holding a total of 6,479,691 shares. Major institutional owners include Vanguard Group Inc., Vanguard Total Stock Market Index Fund Investor Shares (VTSMX), and Sozo Ventures GP II, L.P.. Significant individual owners include Brian Thomas (6.688%) and Sebastián Bernales (3.122%). Jian Irish, the current CEO, directly owns 1.61% of the company's shares.